Certain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation; Termination of Investigation

ing EDIS, please email [email protected] . General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov . Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810. SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on December 22, 2025, based on a complaint filed by AbbVie Inc. of North Chicago, Illinois; ImmunoGen, Inc. of Waltham, Massachusetts; and ImmunoGen Switzerland GmbH (collectively, ``AbbVie''). 90 FR 59867 (Dec. 22, 2025). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into the United States of certain antibody drug conjugates and components thereof and products containing the same by reason of misappropriation of trade secrets, the threat or effect of which is to destroy or substantially injure an industry in the United States or to prevent the establishment of an industry in the United States. Id. The Commission's notice of investigation named as respondents ProfoundBio US Co. of Seattle, Washington; ProfoundBio (Suzhou) Co., Ltd. of Suzhou, China; Genmab A/S of Valby, Denmark; Genmab B.V. of Utrecht, Netherlands; and Genmab US, Inc. of Plainsboro, New Jersey (collectively, ``Respondents''). Id. The Of